- Approval Id
- 5dfc11038c1f07b5
- Drug Approval Emc Name
- Skyrizi 360 mg solution for injection in cartridge
- Drug Name
- Skyrizi 360 mg solution for injection in cartridge
- Company Address
- AbbVie House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4UB, UK
- Company Website
- //www.abbvie.co.uk
- Company Telephone
- +44 (0)1628 561 090
- Company Medical Info Direct Line
- +44 (0)1628 561 092
- Company Medical Info Email
- ukmedinfo@abbvie.com
- Atc Code
- L04AC18
- Legal Category
- Prescription only medicine
- Authorisation Holder
- AbbVie Ltd
Maidenhead
SL6 4UB
UK
- Authorisation Number
- PLGB 41042/0050
- Authorisation Date
- 01 March 2024
- Instruction Authorisation Holder
- AbbVie Ltd
Maidenhead
SL6 4UB
UK
- Instruction Authorisation Number
- PLGB 41042/0050
- Instruction Authorisation Date
- 01 March 2024
- Instruction Composition
- Each cartridge contains 360 mg of risankizumab in 2.4 mL solution (150 mg/mL).
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Solution for injection (injection)
The solution is colourless to yellow and clear to slightly opalescent.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
Crohn's disease
Risankizumab is indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
Ulcerative colitis
Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.4.2 Posology and method of administration
Skyrizi is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Skyrizi is indicated.
Posology
\*Crohn's disease\*
The recommended dose is 600 mg administered by intravenous infusion at Week 0, Week 4, and Week 8, followed by 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the intravenous regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
\*Ulcerative colitis\*
The recommended induction dose is 1 200 mg administered by intravenous (IV) infusion at Week 0, Week 4, and Week 8. Starting at Week 12 and every 8 weeks thereafter, the recommended maintenance dose is based on individual patient presentation:
• A dose of 180 mg administered by subcutaneous injection is recommended for patients with adequate improvement in disease activity after induction
• A dose of 360 mg administered by subcutaneous injection is recommended for patients with inadequate improvement in disease activity after induction
Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the initial intravenous dosing regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
Missed dose
If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.
Special populations
\*Elderly\*
No dose adjustment is required (see section 5.2).
There is limited information in subjects aged ≥65 years.
\*Renal or hepatic impairment\*
No specific studies were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of Skyrizi. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).
\*Paediatric population\*
The safety and efficacy of Skyrizi for the treatment of Crohn's disease in children and adolescents younger than 16 years of age have not yet been established. The safety and efficacy of Skyrizi in children aged 0-17 years for the treatment of ulcerative colitis have not yet been established. Currently available data are described in section 5.1 and 5.2 but no recommendation on posology can be made.
\*Overweight patients\*
No dose adjustment is required (see section 5.2).
Method of administration
Skyrizi is administered by subcutaneous injection.
The injection should be administered in the thigh or abdomen. Patients should not inject into areas where the skin is tender, bruised, erythematous, indurated or damaged.
Patients may self-inject Skyrizi after training in subcutaneous injection technique with the on-body injector. Patients should be instructed to read the 'Instructions for use' provided in the package leaflet before administration.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Clinically important active infections (e.g. active tuberculosis, see section 4.4).4.4 Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections
Risankizumab may increase the risk of infection.
In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.
Tuberculosis
Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Immunisations
Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment (see section 5.2).
Hypersensitivity
Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab (see section 4.8). If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
Excipients with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per cartridge, that is to say essentially 'sodium‑free'.4.5 Interaction with other medicinal products and other forms of interaction
Risankizumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Interactions between risankizumab and inhibitors, inducers, or substrates of medicinal product metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).
Concomitant immunosuppressive therapy
The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics, have not been evaluated.4.6 Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.
Pregnancy
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of risankizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of risankizumab during pregnancy.
Breast-feeding
It is unknown whether risankizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Fertility
The effect of risankizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.4.7 Effects on ability to drive and use machines
Risankizumab has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
Summary of the safety profile
The most frequently reported adverse reactions were upper respiratory infections (15.6% in Crohn's disease and 26.2% in ulcerative colitis).
Tabulated list of adverse reactions
Adverse reactions for risankizumab from clinical studies (Table 1) are listed by MedDRA system organ class and are based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); and very rare (< 1/10 000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
\*\*Table 1: List of adverse reactions\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reactions\*\* |
| Infections and infestations | Very common | Upper respiratory infectionsa |
| Common | Tinea infectionsb |
| Uncommon | Folliculitis |
| Nervous system disorders | Common | Headachec |
| Skin and subcutaneous tissue disorders | Common | Pruritus Rash Eczema |
| Uncommon | Urticaria |
| General disorders and administration site conditions | Common | Fatigued Injection site reactionse |
| Immune system disorders | Rare | Anaphylactic reactions |
| a Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral), tonsillitis, laryngitis, peritonsillar abscess b Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, onychomycosis, tinea infection c Includes: headache, tension headache, sinus headache d Includes: fatigue, asthenia, malaise e Includes: injection site bruising, erythema, haematoma, haemorrhage, irritation, pain, pruritus, reaction, swelling, induration, hypersensitivity, nodule, rash, urticaria, vesicles, warmth; infusion site erythema, extravasation, reaction, swelling | | |
Description of selected adverse reactions
\*Psoriasis\*
\*Infections\*
Over the entire psoriasis programme including long-term exposure to risankizumab, the rate of infections was 75.5 events per 100 subject-years. The majority of cases were non-serious and mild to moderate in severity and did not lead to discontinuation of risankizumab. The rate of serious infections was 1.7 events per 100 subject-years (see section 4.4).
\*Crohn's disease\*
The adverse drug reaction profile observed in patients with Crohn's disease treated with risankizumab was consistent with the adverse drug reaction profile observed in patients across indications. No new adverse reactions were identified in risankizumab Crohn's disease studies.
\*Infections\*
The majority of infections were non‑serious and mild to moderate in severity and did not lead to discontinuation of risankizumab.
The rate of infections in the pooled data from the 12-week induction studies was 83.3 events per 100 subject‑years in subjects treated with risankizumab 600 mg IV compared to 117.7 events per 100 subject‑years in placebo. The rate of serious infections was 3.4 events per 100 subject-years in subjects treated with risankizumab 600 mg IV compared to 16.7 events per 100 subject-years in placebo (see section 4.4).
The rate of infections in the 52‑week maintenance study was 57.7 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 76.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 6.0 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 5.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
\*Ulcerative colitis\*
Overall, the safety profile observed in patients with ulcerative colitis treated with risankizumab was consistent with the safety profile observed in patients across indications.
\*Infections\*
The rate of infections in the pooled data from the 12-week induction study was 78.3 events per 100 subject‑years in subjects treated with risankizumab 1 200 mg intravenously compared to 74.2 events per 100 subject‑years in placebo. The rate of serious infections was 3.0 events per 100 subject-years in subjects treated with risankizumab 1 200 mg intravenously compared to 5.4 events per 100 subject‑years in placebo (see section 4.4).
The rate of infections in the 52-week maintenance study was 67.4 events per 100 subject‑years in subjects treated with risankizumab 180 mg subcutaneously and 56.5 events per 100 subject‑years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 64.6 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 1.1 events per 100 subject-years in subjects treated with risankizumab 180 mg subcutaneously and 0.6 events per 100 subject-years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 2.3 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
\*Immunogenicity\*
As with all therapeutic proteins, there is the potential for immunogenicity with risankizumab. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
For subjects with Crohn's disease treated with risankizumab at the recommended IV induction and SC maintenance doses for up to 64 weeks in CD clinical trials, treatment-emergent anti-drug antibodies and neutralizing antibodies were detected in 3.4% (2/58) and 0% (0/58) of evaluated subjects, respectively.
For subjects with ulcerative colitis treated with risankizumab at the recommended intravenous induction and subcutaneous maintenance doses (180 mg or 360 mg) for up to 64 weeks in ulcerative colitis clinical trials, treatment-emergent anti-drug antibodies and neutralising antibodies were detected in 8.9% (8/90) and 6.7% (6/90) for the 180 mg SC dose, or 4.4% (4/91) and 2.2% (2/91) for the 360 mg SC dose, of evaluated subjects, respectively.
Antibodies to risankizumab including neutralizing antibodies were not associated with changes in clinical response or safety.
Elderly
There is limited safety information in subjects aged ≥65 years.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme:
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store4.9 Overdose
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC18
Mechanism of action
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Pharmacodynamic effects
In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.
In a Phase 2 study of subjects with Crohn's disease, expression of genes associated with the IL-23/Th17 axis were decreased in gut tissue after multiple doses of risankizumab. Reductions in faecal calprotectin (FCP), serum C reactive protein (CRP) and IL-22 were also observed after multiple doses in Phase 3 induction studies in Crohn's patients. Decreases in FCP, CRP and serum IL-22 were maintained out to Week 52 of the maintenance study.
In a Phase 2b/3 study of subjects with ulcerative colitis, statistically significant and clinically meaningful reduction from baseline was observed in the inflammatory biomarkers, FCP and CRP, and in the IL-23 pathway-associated biomarker, serum IL-22, at week 12 of the induction study. Decreases in FCP, CRP and serum IL-22 were maintained out to Week 52 of the maintenance study.
Clinical efficacy and safety
Skyrizi has been shown to improve signs and symptoms and health related quality of life, as well as decrease mucosal inflammation as measured by endoscopy.
\*Crohn's disease\*
The efficacy and safety of risankizumab were assessed in 1 419 subjects with moderately to severely active Crohn's disease in three multicentre, randomised, double-blind, placebo‑controlled clinical studies. Enrolled subjects were 16 years of age or older with a Crohn's Disease Activity Index (CDAI) of 220 to 450, an average daily stool frequency (SF) ≥4 and/or average daily abdominal pain score (APS) ≥2, and a Simple Endoscopic Score for CD (SES-CD) of ≥6, or ≥4 for isolated ileal disease, excluding the narrowing component and confirmed by a central reviewer.
There were two 12‑week intravenous induction studies (ADVANCE and MOTIVATE), which included a 12‑week extension period for subjects who did not achieve SF/APS clinical response at Week 12 (≥ 30% decrease in SF and/or ≥ 30% decrease in APS and both not worse than baseline) at Week 12. ADVANCE and MOTIVATE were followed by a 52‑week randomized withdrawal study of subcutaneous maintenance treatment (FORTIFY) that enrolled subjects with SF/APS clinical response to IV induction treatment, representing at least 64 weeks of therapy.
\*ADVANCE and MOTIVATE\*
In studies ADVANCE and MOTIVATE, subjects were randomized to receive risankizumab at either 600 mg (recommended dose), 1 200 mg, or placebo, at Week 0, Week 4, and Week 8.
In ADVANCE, 58% (491/850) subjects had failed or were intolerant to treatment with one or more biologic therapies (prior biologic failure), and 42% (359/850) had failed or were intolerant to therapy with conventional therapies but not biologic therapies (without prior biologic failure). In ADVANCE, among the subjects without prior biologic failure, (87%) 314/359 were naïve to biologic therapy and the remaining 13% had received a biologic but never failed or demonstrated intolerance. All patients in MOTIVATE had prior biologic failure.
The co-primary endpoints were clinical remission based on SF and APS (average daily SF ≤2.8 and not worse than baseline and average daily AP score ≤1 and not worse than baseline) at Week 12, and endoscopic response (greater than 50% decrease in SES‑CD from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease) at Week 12. In both studies, a greater proportion of subjects treated with Skyrizi achieved clinical remission at Week 12 and endoscopic response at Week 12 compared to placebo (Table 2). Enhanced SF/APS clinical response and clinical remission were significant as early as Week 4 in subjects treated with Skyrizi and continued to improve through Week 12.
Additional secondary endpoints measured at Week 12 included the proportion of subjects with enhanced SF/APS clinical response (with ≥60% decrease in average daily SF and/or ≥35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission), endoscopic remission (SES-CD ≤4 and at least a 2 point reduction versus Baseline and no subscore greater than 1 in any individual variable), mucosal healing (SES-CD ulcerated surface subscore of 0 in subjects with a subscore of >1 at Baseline), a decrease of least 100 points in baseline CDAI, and a CDAI <150 at Week 12.
\*\*Table 2. Efficacy results in ADVANCE and MOTIVATE\*\*
| | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | \*\*ADVANCE\*\* | | | \*\*MOTIVATE\*\* | | |
| \*\*Placebo IV\*\* \*\*(N=175)\*\* \*\*%\*\* | \*\*Skyrizi\*\* \*\*600 mg IV\*\* \*\*(N=336)\*\* \*\*%\*\* | \*\*Treatment differencee (95% CI)\*\* | \*\*Placebo IV\*\* \*\*(N=187)\*\* \*\*%\*\* | \*\*Skyrizi\*\* \*\*600 mg IV\*\* \*\*(N=191)\*\* \*\*%\*\* | \*\*Treatment differencee\*\* \*\*(95% CI)\*\* |
| \*\*Clinical remission at Week 12a\*\* | 22% | 43% | 22% [14%, 30%]b | 19% | 35% | 15% [6%, 24%]c |
| \*\*Endoscopic response at Week 12a\*\* | 12% | 40% | 28% [21%, 35%]b | 11% | 29% | 18% [10%, 25%]b |
| \*\*Enhanced SF/APS clinical response at Week 4\*\* | 31% | 46% | 15% [6%, 23%]c | 32% | 45% | 14% [4%, 23%]d |
| \*\*Enhanced SF/APS clinical response at Week 12\*\* | 42% | 63% | 21% [12%, 30%]b | 39% | 62% | 23% [13%, 33%]b |
| \*\*Mucosal healing at Week 12\*\* | 8% | 21% | 14% [8%, 19%]b | 4% | 14% | 9% [4%, 15%]c |
| \*\*Endoscopic remission at Week 12\*\* | 9% | 24% | 15% [9%, 21%]b | 4% | 19% | 15% [9%, 21%]b |
| a Co-primary endpoints. b Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p<0.001). c Statistically significant under multiplicity-control for Skyrizi vs placebo (p≤0.01). d Nominal p ≤ 0.01 SKYRIZI vs placebo comparison. e Adjusted treatment difference. | | | | | | |
At Week 4, a higher proportion of subjects treated with Skyrizi achieved a CDAI <150 compared to placebo (ADVANCE, Skyrizi=18%, placebo=10%, p≤0.05; MOTIVATE, Skyrizi=21%, placebo=11%, p≤0.01).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved a CDAI<150 compared to placebo (ADVANCE, Skyrizi=45%, placebo=25%, p<0.001; MOTIVATE, Skyrizi=42%, placebo=20%, p<0.001).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved a decrease of at least 100 points in baseline CDAI compared to placebo (ADVANCE, Skyrizi=60%, placebo=37%, p<0.001; MOTIVATE, Skyrizi=60%, placebo=30%, p<0.001).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved both enhanced SF/APS clinical response and endoscopic response at Week 12 compared to placebo (ADVANCE, Skyrizi=31%, placebo=8%, p<0.001; MOTIVATE, Skyrizi=21%, placebo=7%, p<0.001).
The results for the co-primary endpoints for subjects with and without prior biologic failure are presented in Table 3.
\*\*Table 3. Efficacy results at Week 12 in subjects with prior biologic treatment failure and subjects without prior biologic failure in ADVANCE\*\*
| | | |
| --- | --- | --- |
| | \*\*ADVANCE\*\* | |
| \*\*Placebo IV\*\* | \*\*Skyrizi 600 mg\*\* |
| \*\*Clinical remission per SF/AP Score\*\* | | |
| Prior biologic failure | 23% (N=97) | 41% (N=195) |
| Without prior biologic failure | 21% (N=78) | 48% (N=141) |
| \*\*Endoscopic response\*\* | | |
| Prior biologic failure | 11% (N=97) | 33% (N=195) |
| Without prior biologic failure | 13% (N=78) | 50% (N=141) |
In ADVANCE, a higher proportion of subjects treated with Skyrizi with and without prior biologic failure achieved CDAI<150 compared to placebo (With prior biologic failure, Skyrizi=42%, placebo=26%; Without prior biologic failure, Skyrizi=49%, placebo=23%).
\*CD-related hospitalisations\*
Rates of CD-related hospitalisations through Week 12 were lower in subjects treated with Skyrizi compared to placebo (ADVANCE, Skyrizi=3%, placebo=12%, p<0.001; MOTIVATE, Skyrizi=3%, placebo=11%, p≤0.01).
\*FORTIFY\*
The maintenance study FORTIFY evaluated 462 subjects with SF/APS clinical response to 12 weeks of Skyrizi IV induction treatment in studies ADVANCE and MOTIVIATE. Subjects were randomized to continue to receive a maintenance regimen of Skyrizi 360 mg SC (recommended dose), or Skyrizi 180 mg SC every 8 weeks, or to withdraw from Skyrizi induction and receive placebo SC every 8 weeks for up to 52 weeks.
The co-primary endpoints were clinical remission at Week 52 and, endoscopic response at Week 52. Co-primary endpoints were also measured in subjects with and without prior biologic failure (see Table 4).
Secondary endpoints measured at Week 52 included enhanced SF/APS clinical response, maintenance of clinical remission (clinical remission at Week 52 in subjects with clinical remission at Week 0), mucosal healing, endoscopic remission, deep remission (clinical remission and endoscopic remission), and CDAI <150.
\*\*Table 4. Efficacy results in FORTIFY at Week 52 (64 weeks from initiation of induction dose)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*FORTIFY\*\* | | |
| \*\*Skyrizi IV induction/ Placebo SCg\*\* \*\*(N=164) %\*\* | \*\*Skyrizi IV induction/ Skyrizi\*\* \*\*360 mg SC\*\* \*\*(N=141) %\*\* | \*\*Treatment difference (95% CI)\*\* |
| \*\*Clinical remissiona\*\* | 40% | 52% | 15% [5%, 25%]b,h |
| Prior biologic failure | 34% (N=123) | 48% (N=102) | 14% [1%,27%] |
| Without prior biologic failure | 56% (N=41) | 62% (N=39) | 5% [-16%,27%] |
| \*\*Endoscopic responsea\*\* | 22% | 47% | 28% [19%, 37%]c,h |
| Prior biologic failure | 20% (N=123) | 44% (N=102) | 23% [11%, 35%] |
| Without biologic failure | 27% (N=41) | 54% (N=39) | 27% [6%, 48%] |
| \*\*Enhanced SF/APS clinical response\*\* | 49% | 59% | 13% [2%, 23%]f,h |
| \*\*Maintenance of clinical remission\*\* | (N = 91) 51% | (N = 72) 69% | 21% [6%, 35%]e,h |
| \*\*Endoscopic remission\*\* | 13% | 39% | 28% [20%, 37%]d,h |
| \*\*Mucosal healing\*\* | (N = 162) 10% | (N = 141) 31% | 22% [14%, 30%]d,h |
| a Co-primary endpoints b Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p≤0.01). c Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p≤0.001). d Nominal p<0.001 Skyrizi vs placebo comparison. e Nominal p≤0.01 Skyrizi vs placebo comparison. f Nominal p≤0.05 Skyrizi vs placebo comparison. g The induction-only group consisted of subjects who achieved clinical response to Skyrizi induction therapy and were randomized to receive placebo in the maintenance study (FORTIFY). h Adjusted treatment difference. | | | |
Deep remission at Week 52 was observed at higher rates in subjects treated with Skyrizi IV/Skyrizi SC compared to subjects who received Skyrizi IV/placebo SC (28% vs. 10%, respectively, p<0.001).
At Week 52, a higher proportion of subjects treated with Skyrizi IV/Skyrizi SC achieved CDAI < 150 compared to Skyrizi IV/placebo SC (52% vs. 41%, respectively, p≤0.01). A higher proportion of subjects treated with Skyrizi IV/Skyrizi SC achieved a decrease of at least 100 points in baseline CDAI score compared to subjects treated with Skyrizi IV/placebo SC (62% vs. 48%, respectively, p≤ 0.01).
91 subjects who did not demonstrate SF/APS clinical response 12 weeks after Skyrizi induction in studies ADVANCE and MOTIVATE received subcutaneous 360 mg dose of Skyrizi at Week 12 and Week 20. Of these subjects, 64% (58/91) achieved SF/APS clinical response at Week 24; 33 of the subjects achieving SF/APS clinical response enrolled in FORTIFY and continued receiving Skyrizi 360 mg SC every 8 weeks for up to 52 weeks. Among these subjects, 55% (18/33) achieved clinical remission and 45% (15/33) achieved endoscopic response at Week 52.
During FORTIFY, 30 subjects had loss of response to Skyrizi 360 mg SC treatment and received rescue treatment with Skyrizi (1 200 mg IV single dose, followed by 360 mg SC every 8 weeks). Of these subjects, 57% (17/30) achieved SF/APS clinical response at Week 52. In addition, 20% (6/30) and 34% (10/29) of subjects achieved clinical remission and endoscopic response at Week 52, respectively.
\*Health-related and quality of life outcomes\*
Health-related quality of life was assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Health Survey (SF-36), and the European Quality of Life 5 Dimensions (EQ-5D). Improvement in fatigue was evaluated by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale.
At Week 12 of ADVANCE and MOTIVATE, subjects treated with Skyrizi achieved clinically meaningful improvements from baseline in IBDQ total score, all IBDQ domain scores (bowel symptoms, systemic function, emotional function, and social function), SF-36 Physical and Mental Component Summary Score, EQ-5D VAS, and FACIT-Fatigue compared to placebo.
Subjects treated with Skyrizi experienced more improvements in work productivity compared to placebo, as assessed by the WPAI-CD questionnaire at Week 12. Specifically, greater reductions in impairment while working, overall work impairment, and activity impairment was demonstrated in ADVANCE; and greater reduction in activity impairment was demonstrated in MOTIVATE.
Compared to placebo, subjects treated with Skyrizi achieved clinically meaningful improvements from baseline in Crohn's-related symptoms and sleep impact as assessed by Crohn's Symptom Severity (CSS) questionnaire at Week 12. These improvements were maintained in subjects treated with Skyrizi IV/Skyrizi SC in FORTIFY through Week 52.
\*Ulcerative colitis\*
The efficacy and safety of risankizumab was assessed in subjects with moderately to severely active ulcerative colitis in two multicentre, randomised, double-blind, placebo-controlled clinical studies. Enrolled subjects were ≥ 18 and ≤ 80 years of age with adapted Mayo Score (aMS) of 5 to 9 (using the Mayo scoring system, excluding Physician's Global Assessment) with an endoscopic subscore (ES) of 2 or 3 on screening endoscopy, confirmed by central review.
The 12-week intravenous induction study (INSPIRE) included a 12-week extension period for subjects who did not achieve clinical response [defined as a decrease from baseline in the aMS ≥ 2 points and ≥ 30% from baseline, and a decrease in rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1] at Week 12. INSPIRE was followed by a 52-week randomised withdrawal study of subcutaneous maintenance treatment (COMMAND) that enrolled subjects with clinical response to 12 weeks of risankizumab intravenous induction treatment, representing at least 64 weeks of therapy.
\*INSPIRE\*
In study INSPIRE, 975 subjects were randomised and received either risankizumab 1 200 mg or placebo, at Week 0, Week 4, and Week 8.
In INSPIRE, 52% (503/975) of subjects had failed (inadequate response or intolerance) one or more biologics therapies, JAK inhibitors, and/or S1P receptor modulators. Of these 503 subjects, 488 (97%) failed biologics and 90 (18%) failed JAK inhibitors.
Enrolled subjects were permitted to use a stable dose of oral corticosteroids (up to 20 mg/day prednisone or equivalent), immunomodulators, and aminosalicylates. At baseline in INSPIRE, 36% of subjects received corticosteroids, 17% of subjects received immunomodulators and 73% of subjects received aminosalicylates. Patient disease activity was moderate (aMS ≤7) in 58% of subjects and severe (aMS >7) in 42% of subjects
In INSPIRE, a significantly greater proportion of subjects treated with risankizumab achieved the primary endpoint of clinical remission per aMS [defined as stool frequency subscore (SFS) ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability] at Week 12 compared to placebo (Table 5). Results of the primary endpoint and key secondary endpoints are listed in Table 5.
\*\*Table 5. Efficacy results in INSPIRE at Week 12\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Endpoint\*\* | \*\*Placebo IV\*\* \*\*(N=325)\*\* \*\*%\*\* | \*\*Risankizumab\*\* \*\*1 200 mg IV\*\* \*\*(N=650)\*\* \*\*%\*\* | \*\*Treatment difference\*\* \*\*(95% CI)\*\* |
| \*\*Disease activity and UC symptoms\*\* | | | |
| \*\*Clinical remissionab\*\* | 6% | 20% | 14%f [10%, 18%] |
| With biologic and/or JAK inhibitor failure | 4% (N=170) | 11% (N=333) | 7% [3%, 12%] |
| Without biologic and/or JAK inhibitor failure | 8% (N=155) | 30% (N=317) | 21% [15%, 28%] |
| \*\*Clinical responsec\*\* | 36% | 64% | 29%f [22%, 35%] |
| With biologic and/or JAK inhibitor failure | 31% (N=170) | 55% (N=333) | 24% [15%, 33%] |
| Without biologic and/or JAK inhibitor failure | 41% (N=155) | 74% (N=317) | 33% [24%, 42%] |
| \*\*Endoscopic and histologic assessment\*\* | | | |
| \*\*Mucosal healingd\*\* | 12% | 37% | 24%f [19%, 29%] |
| With biologic and/or JAK inhibitor failure | 10% (N=170) | 26% (N=333) | 16% [9%, 22%] |
| Without biologic and/or JAK inhibitor failure | 14% (N=155) | 48% (N=317) | 33% [26%, 41%] |
| \*\*Histologic-endoscopic mucosal healinge\*\* | 8% | 24% | 17%f [12%, 21%] |
| With biologic and/or JAK inhibitor failure | 7% (N=170) | 16% (N=333) | 9% [3%, 14%] |
| Without biologic and/or JAK inhibitor failure | 8% (N=155) | 33% (N=317) | 25% [18%, 32%] |
| a Primary endpoint b Clinical remission per aMS: SFS ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability c Clinical response per aMS: decrease from Baseline ≥ 2 points and ≥ 30%, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1 d ES ≤ 1 without the evidence of friability e ES ≤ 1 without the evidence of friability and Geboes score ≤ 3.1 (indicating neutrophil infiltration in <5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue) f p < 0.00001, adjusted treatment difference (95% CI) | | | |
\*Clinical disease activity and symptoms\*
The partial adapted Mayo score (paMS) is composed of SFS and RBS. Clinical response per paMS is defined as a decrease of ≥1 point and ≥30% from Baseline and a decrease in RBS ≥1 or an absolute RBS ≤1. The results of clinical response per paMS over time in INSPIRE are shown in Figure 1. Onset of efficacy was rapid with a greater proportion of subjects treated with risankizumab achieving clinical response as early as Week 4 compared to placebo (52% vs 31%, respectively, p < 0.00001).
\*\*Figure 1. Proportion of subjects achieving clinical response per paMS over time in induction study INSPIRE\*\*
A significantly greater proportion of subjects treated with risankizumab compared to placebo had no abdominal pain (36% vs 26%, respectively, p < 0.01) and no bowel urgency (44% vs 28%, respectively, p < 0.00001) at Week 12.
\*Other UC symptoms\*
Number of faecal incontinence episodes per week was reduced in a significantly greater amount in subjects treated with risankizumab compared to placebo at Week 12 (change from baseline in risankizumab = -3.8, placebo = -2.2, p = 0.00003).
The proportion of subjects who had no nocturnal bowel movements was significantly greater in subjects treated with risankizumab compared to placebo at Week 12 (67% vs 43%, respectively, p < 0.00001).
The proportion of subjects who had no tenesmus was significantly greater in subjects treated with risankizumab compared to placebo at Week 12 (49% vs 30%, respectively, p < 0.00001).
Number of days with sleep interruption due to UC symptoms per week were reduced in a significantly greater amount in subjects treated with risankizumab compared to placebo at Week 12 (change from baseline in risankizumab = -2.5, placebo = -1.5, p < 0.00001).
\*UC-related hospitalisations\*
Rates of UC-related hospitalisations through Week 12 were significantly lower in subjects treated with risankizumab compared to placebo (1% vs 6%, respectively, p < 0.00001).
\*Extended treatment in week 12 non-responders\*
A total of 141 subjects who did not demonstrate clinical response at week 12 of risankizumab induction in INSPIRE received either subcutaneous 180 mg or 360 mg dose of risankizumab at Week 12 and Week 20. Of the 71 subjects who received risankizumab 180 mg SC and 70 subjects who received risankizumab 360 mg SC, 56% and 57% achieved clinical response at Week 24, respectively.
COMMAND
The maintenance study COMMAND evaluated 548 subjects with clinical response after 12 weeks of risankizumab IV induction treatment in study INSPIRE. Subjects were randomised to receive a maintenance regimen of risankizumab 180 mg SC or 360 mg SC every 8 weeks, or to withdraw from risankizumab induction and receive placebo SC every 8 weeks for up to 52 weeks.
In COMMAND, 75% (411/548) of subjects had failed (inadequate response or intolerance) one or more biologics therapies, JAK inhibitors, and/or S1P receptor modulators prior to induction baseline. Of these 411 subjects, 407 (99%) failed biologics and 78 (19%) failed JAK inhibitors.
In COMMAND, a significantly greater proportion of the above 548 subjects treated with risankizumab 180 mg SC or risankizumab 360 mg SC achieved the primary endpoint of clinical remission per aMS at Week 52 compared to placebo (see Table 6). Results of the primary endpoint and key secondary endpoints are listed in Table 6.
\*\*Table 6. Efficacy results in COMMAND at week 52 (64 weeks from initiation of induction dose)\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Endpoint\*\* | \*\*Risankizumab IV induction/ Placebo SC+\*\* \*\*(N=183) %\*\* | \*\*Risankizumab IV induction/ Risankizumab 180 mg SC\*\* \*\*(N=179) %\*\* | \*\*Risankizumab IV induction/ Risankizumab 360 mg SC\*\* \*\*(N=186) %\*\* | \*\*Treatment difference\*\* \*\*(97.5% CI)++\*\* | |
| \*\*Risankizumab IV induction/ Risankizumab 180 mg SC\*\* | \*\*Risankizumab IV induction/ Risankizumab 360 mg SC\*\* |
| \*\*Disease activity and UC symptoms\*\* | | | | | |
| \*\*Clinical remissionab\*\* | 25% | 40% | 38% | 16%h [6%, 27%] | 14%h [4%, 24%] |
| With biologic and/or JAK inhibitor failure | 23% (N=138) | 37% (N=134) | 29% (N=139) | 13% [1%, 26%] | 6% [-6%, 18%] |
| Without biologic and/or JAK inhibitor failure | 31% (N=45) | 51% (N=45) | 62% (N=47) | 20% [-3%, 43%] | 31% [8%, 53%] |
| \*\*Maintenance of clinical remissionc\*\* | 40% (N=53) | 70% (N=44) | 50% (N=40) | 29%h [7%, 51%] | 13%k [-11%, 36%] |
| With biologic and/or JAK inhibitor failure | 37% (N=35) | 65% (N=26) | 44% (N=25) | 28% [0%, 56%] | 7% [-22%, 36%] |
| Without biologic and/or JAK inhibitor failure | 44% (N=18) | 77% (N=18) | 60% (N=15) | 33% [-2%, 67%] | 16% [-23%, 54%] |
| \*\*Corticosteroid-free clinical remissiond\*\* | 25% | 40% | 37% | 16% h [6%, 26%] | 14% h [3%, 24%] |
| With biologic and/or JAK inhibitor failure | 23% (N=138) | 36% (N=134) | 29% (N=139) | 13% [0%, 25%] | 6% [-6%, 18%] |
| Without biologic and/or JAK inhibitor failure | 31% (N=45) | 51% (N=45) | 60% (N=47) | 20% [-3%, 43%] | 28% [6%, 51%] |
| \*\*Clinical responsee\*\* | 52% | 68% | 62% | 17%i [6%, 28%] | 11%j [0%, 23%] |
| With biologic and/or JAK inhibitor failure | 46% (N=138) | 63% (N=134) | 57% (N=139) | 18% [4%, 31%] | 11% [-2%, 25%] |
| Without biologic and/or JAK inhibitor failure | 71% (N=45) | 82% (N=45) | 79% (N=47) | 11% [-9%, 31%] | 8% [-13%, 28%] |
| \*\*Endoscopic and histologic assessment\*\* | | | | | |
| \*\*Mucosal healingf\*\* | 32% | 51% | 48% | 20% h [9%, 31%] | 17% h [7%, 28%] |
| With biologic and/or JAK inhibitor failure | 30% (N=138) | 48% (N=134) | 39% (N=139) | 17% [4%, 30%] | 8% [-4%, 21%] |
| Without biologic and/or JAK inhibitor failure | 36% (N=45) | 60% (N=45) | 76% (N=47) | 24% [1%, 47%] | 41% [19%, 62%] |
| \*\*Histologic-endoscopic mucosal healingg\*\* | 23% | 43% | 42% | 20%h [10%, 31%] | 20% h [10%, 30%] |
| With biologic and/or JAK inhibitor failure | 22% (N=138) | 39% (N=134) | 33% (N=139) | 17% [5%, 29%] | 11% [-1%, 23%] |
| Without biologic and/or JAK inhibitor failure | 29% (N=45) | 55% (N=45) | 69% (N=47) | 26% [3%, 49%] | 40% [19%, 62%] |
| + The induction-only group consisted of subjects who achieved clinical response to risankizumab induction therapy and were randomised to receive placebo in the maintenance study (COMMAND). ++ Adjusted difference for the overall treatment difference. a Primary endpoint b Clinical remission per aMS: SFS ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability c Clinical remission per aMS at Week 52 among subjects who achieved clinical remission at the end of induction treatment d Clinical remission per aMS at Week 52 and corticosteroid-free for ≥90 days e Clinical response per aMS: decrease from Baseline ≥ 2 points and ≥ 30%, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1 f ES of ≤ 1 without the evidence of friability g ES ≤ 1 without the evidence of friability and Geboes score ≤ 3.1 (indicating neutrophil infiltration in <5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue) h Statistically significant under multiplicity-control for risankizumab vs placebo comparison (p ≤ 0.01). i Nominal p ≤ 0.01 risankizumab vs placebo comparison j Nominal p ≤ 0.05 risankizumab vs placebo comparison k p = 0.2234 | | | | | |
\*Clinical disease activity and symptoms\*
A significantly greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC compared to risankizumab IV/placebo had no abdominal pain (47% vs 30%, respectively, p < 0.001) and no bowel urgency (54% vs 31%, respectively, p < 0.00001) at Week 52. A greater proportion of subjects treated with risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo had no bowel urgency (49% vs 31%, respectively, p < 0.001) at Week 52, and a numerically higher proportion of subjects had no abdominal pain compared to risankizumab IV/placebo (38% vs 30%, respectively, p = 0.0895) at Week 52.
\*Other UC symptoms\*
The proportion of subjects who had no nocturnal bowel movements was greater in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo at Week 52 (42% and 43% vs 30%, p < 0.01 and p < 0.001, respectively).
The proportion of subjects who had no tenesmus was greater in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo at Week 52 (37% and 37% vs 23%, respectively, p < 0.01).
\*UC-related hospitalisations\*
Occurrence of UC-related hospitalisations through Week 52 were numerically lower in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo (0.6 per 100 subject-years and 1.2 per 100 subject-years vs 3.1 per 100 subject-years, p = 0.0949 and p = 0.2531, respectively).
\*Endoscopic and histologic assessment\*
Endoscopic remission (normalisation of the endoscopic appearance of the mucosa) was defined as ES of 0. At Week 12 of INSPIRE, a significantly greater proportion of subjects treated with risankizumab compared to placebo achieved endoscopic remission (11% vs 3%, respectively, p < 0.00001). At Week 52 of COMMAND, a significantly greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo achieved endoscopic remission (23% and 24% vs 15%, respectively, p < 0.05).
Deep mucosal healing was defined as ES of 0 and Geboes score < 2.0 (indicating no neutrophil in crypts or lamina propria and no increase in eosinophil, no crypt destruction, and no erosions, ulcerations or granulation tissue). At Week 12 of INSPIRE, a significantly greater proportion of subjects treated with risankizumab compared to placebo achieved deep mucosal healing (6% vs 1%, respectively, p < 0.00001). At Week 52 of COMMAND, a numerically higher proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo achieved deep mucosal healing (13% and 16% vs 10%, p = 0.2062 and p = 0.0618, respectively).
In COMMAND, maintenance of mucosal healing at Week 52 (ES ≤1 without friability) was seen in a greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo among subjects who achieved mucosal healing at the end of induction (74% and 54% vs 47%, p < 0.01 and p = 0.5629, respectively).
\*Rescue treatment\*
During COMMAND, subjects who had loss of response to risankizumab SC treatment received rescue treatment with risankizumab (a single IV induction dose, followed by 360 mg SC every 8 weeks). Among these subjects, in the risankizumab 180 mg SC and risankizumab 360 mg SC treatment group, 85% (17/20) and 74% (26/35) achieved clinical response at Week 52, respectively. In addition, 24% (6/25) and 35% (13/37) of subjects achieved clinical remission per aMS, and 38% (10/26) and 45% (17/38) of subjects achieved endoscopic improvement at Week 52 in the risankizumab 180 mg SC and risankizumab 360 mg SC treatment group, respectively.
\*Week 24 responders\*
A total of 100 subjects did not demonstrate clinical response after 12 weeks of induction treatment, received either subcutaneous 180 mg (N=56) or 360 mg (N=44) dose of risankizumab at Week 12 and Week 20, demonstrated clinical response at week 24, and continued receiving risankizumab 180 mg or 360 mg SC every 8 weeks for up to 52 weeks in COMMAND. Among these subjects, 46% and 45% achieved clinical response per aMS at Week 52, and 18% and 23% achieved clinical remission per aMS at Week 52, for risankizumab 180 mg and 360 mg SC respectively.
\*Health-related and quality of life outcomes\*
Subjects treated with risankizumab achieved clinically meaningful improvements from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) (bowel symptoms, systemic function, emotional function, and social function) compared to placebo. Changes from baseline in IBDQ total score at Week 12 with risankizumab compared to placebo were 42.6 and 24.3, respectively. Changes from baseline in IBDQ total score at Week 52 were 52.6, 50.3 and 35.0 in subjects treated with risankizumab IV/risankizumab 180 mg SC, risankizumab IV/risankizumab 360 mg SC and risankizumab IV/placebo, respectively.
Subjects receiving risankizumab experienced significantly greater improvement from baseline in fatigue, as measured by FACIT-F score at week 12 compared to placebo. Changes from baseline in FACIT-F score at Week 12 with risankizumab compared to placebo were 7.9 and 3.3, respectively. Changes from baseline in FACIT-F score at Week 52 were 10.9, 10.3 and 7.0 in subjects treated with risankizumab IV/risankizumab 180 mg SC, risankizumab IV/risankizumab 360 mg SC and risankizumab IV/placebo, respectively.
Paediatric population
The Medicines and Healthcare products Regulatory Agency has deferred the obligation to submit the results of studies with Skyrizi in one or more subsets of the paediatric population in the treatment of Crohn's disease and ulcerative colitis(see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
The pharmacokinetics of risankizumab was similar between plaque psoriasis and psoriatic arthritis, and between Crohn's disease and ulcerative colitis.
Absorption
Risankizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure across dose ranges of 18 to 360 mg and 0.25 to 1 mg/kg administered subcutaneously, and 200 to 1 800 mg and 0.01 to 5 mg/kg administered intravenously.
Following subcutaneous dosing of risankizumab, peak plasma concentrations were achieved between 3‑14 days after dosing with an estimated absolute bioavailability of 74-89%. With dosing of 150 mg at Week 0, Week 4 and every 12 weeks thereafter, estimated steady-state peak and trough plasma concentrations are 12 and 2 µg/mL, respectively.
In subjects with Crohn's disease treated with 600 mg IV induction dose at Weeks 0, 4, and 8 followed by 360 mg SC maintenance dose at Week 12 and every 8 weeks thereafter, maximum median peak and trough concentrations are estimated to be 156 and 38.8 µg/mL respectively during the induction period (Weeks 8-12) and steady state median peak and trough concentrations are estimated to be 28.0 and 8.13 ug/mL respectively during the maintenance period (Weeks 40-48).
In subjects with ulcerative colitis treated with 1 200 mg IV induction dose at weeks 0, 4, and 8 followed by 180 mg or 360 mg SC maintenance dose at Week 12 and every 8 weeks thereafter, maximum median peak and trough concentrations are estimated to be 350 and 87.7 µg/mL respectively during the induction period (Weeks 8-12) and steady-state median peak and trough concentrations are estimated to be 19.6 and 4.64 µg/mL for the 180 mg SC dose and 39.2 and 9.29 µg/mL for the 360 mg SC dose, respectively, during the maintenance period (weeks 40-48).
Distribution
The mean (±standard deviation) steady-state volume of distribution (Vss) of risankizumab was 11.4 (±2.7) L in Phase 3 studies in subjects with psoriasis, indicating that the distribution of risankizumab is primarily confined to the vascular and interstitial spaces. In a typical 70 kg subject with Crohn's disease, Vss was 7.68 L.
Biotransformation
Therapeutic IgG monoclonal antibodies are typically degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs. Risankizumab is not expected to be metabolised by cytochrome P450 enzymes.
Elimination
The mean (±standard deviation) systemic clearance (CL) of risankizumab was 0.3 (±0.1) L/day in Phase 3 studies in subjects with psoriasis. The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in subjects with psoriasis. For a typical 70 kg subject with Crohn's disease, CL was 0.30 L/day and terminal elimination half-life was 21 days.
As an IgG1 monoclonal antibody, risankizumab is not expected to be filtered by glomerular filtration in the kidneys or to be excreted as an intact molecule in the urine.
Linearity/non-linearity
Risankizumab exhibited linear pharmacokinetics with approximately dose-proportional increases in systemic exposure (Cmax and AUC) in the evaluated dose ranges of 18 to 360 mg or 0.25 to 1 mg/kg subcutaneous administration and 200 to 1 800 mg and 0.01 to 5 mg/kg administered intravenously in healthy subjects or subjects with psoriasis, Crohn's disease or ulcerative colitis.
Interactions
Interaction studies were conducted in subjects with plaque psoriasis, Crohn's disease, or ulcerative colitis to assess the effect of repeated administration of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) sensitive probe substrates. The exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate) and midazolam (CYP3A substrate) following risankizumab treatment were comparable to their exposures prior to risankizumab treatment, indicating no clinically meaningful interactions through these enzymes.
Population pharmacokinetic analyses indicated that risankizumab exposure was not impacted by concomitant medicinal products used by some subjects with plaque psoriasis during the clinical studies. Similar lack of impact by concomitant medications was observed based on population pharmacokinetic analyses in Crohn's disease or ulcerative colitis.
Special populations
\*Paediatric population\*
The pharmacokinetics of risankizumab in paediatric subjects under 16 years of age has not been established. Risankizumab exposures in 16- to 17‑year-old subjects with Crohn's disease were similar to those in adults. Age was not found to have any significant impact on risankizumab exposures based on the population pharmacokinetic analyses.
\*Elderly\*
Of the 2 234 subjects with plaque psoriasis exposed to risankizumab, 243 were 65 years or older and 24 subjects were 75 years or older. Of the 1 574 subjects with Crohn's disease exposed to risankizumab, 72 were 65 years or older. Of the 1 512 subjects with ulcerative colitis exposed to risankizumab, 103 were 65 years or older and 8 subjects were 75 years or older. No overall differences in risankizumab exposure were observed between older and younger subjects who received risankizumab.
\*Patients with renal or hepatic impairment\*
No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab. Based on population pharmacokinetic analyses, serum creatinine levels, creatinine clearance, or hepatic function markers (ALT/AST/bilirubin) did not have a meaningful impact on risankizumab clearance in subjects with psoriasis, Crohn's disease, or ulcerative colitis.
As an IgG1 monoclonal antibody, risankizumab is mainly eliminated via intracellular catabolism and is not expected to undergo metabolism via hepatic cytochrome P450 enzymes or renal elimination.
\*Body weight\*
Risankizumab clearance and volume of distribution increase as body weight increases which may result in reduced efficacy in subjects with high body weight (>130 kg). However, this observation is based on a limited number of subjects with plaque psoriasis. Body weight had no clinically meaningful impact on risankizumab exposure or efficacy in psoriatic arthritis, Crohn's disease, or ulcerative colitis. No dose adjustment based on body weight is currently recommended.
\*Gender or race\*
The clearance of risankizumab was not significantly influenced by gender or race in adult subjects with plaque psoriasis, Crohn's disease or ulcerative colitis. No clinically meaningful differences in risankizumab exposure were observed in Chinese or Japanese subjects compared to Caucasian subjects in clinical pharmacokinetic studies in healthy volunteers.5.3 Preclinical safety data
Nonclinical data revealed no special hazard for humans based on repeat-dose toxicity studies including safety pharmacology evaluations and an enhanced pre- and post- natal developmental toxicity study in cynomolgus monkeys at doses of up to 50 mg/kg/week, producing exposures 10 times the clinical exposures during induction at a dose of 600 mg IV every 4 weeks and 39 times the clinical exposures for maintenance when given 360 mg SC every 8 weeks for Crohn's disease. For ulcerative colitis, exposures were 5 times the clinical exposures during induction at a dose of 1 200 mg intravenously every 4 weeks and 65 or 32 times the clinical exposures for maintenance when given 180 or 360 mg SC every 8 weeks.
Mutagenicity and carcinogenicity studies have not been conducted with risankizumab. In a 26-week chronic toxicology study in cynomolgus monkeys at doses of up to 50 mg/kg/week (7 times the clinical exposures during induction at a dose of 600 mg IV every 4 weeks and 28 times the clinical exposures for maintenance when given 360 mg SC every 8 weeks for Crohn's disease and 3 times the clinical exposures during induction at a dose of 1 200 mg intravenously every 4 weeks and 45 or 23 times the clinical exposures for maintenance when given 180 or 360 mg SC every 8 weeks for ulcerative colitis), there were no pre-neoplastic or neoplastic lesions observed and no adverse immunotoxicity or cardiovascular effects were noted.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Sodium acetate trihydrate
Acetic acid
Trehalose dihydrate
Polysorbate 20
Water for injections6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
24 months6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C). Do not freeze.
The cartridge may be stored out of the refrigerator (up to a maximum of 25°C) for up to 24 hours.
Keep the cartridge in the outer carton in order to protect from light.6.5 Nature and contents of container
A 360 mg solution in a single‑use cartridge made with cyclic olefin resin with coated chlorobutyl rubber septum and coated chlorobutyl rubber piston as product-contact materials, and a resin cap. The cartridge assembly is co-packed with an on-body injector (administration device). The fluid path within the on-body injector contains polyvinyl chloride tubing and a stainless steel 29‑gauge needle. The on-body injector contains silver oxide-zinc batteries and an adhesive skin patch made from polyester with an acrylic adhesive. The administration device is designed for use with the provided 360 mg cartridge.
Skyrizi 360 mg is available in packs containing 1 cartridge and 1 on-body injector.6.6 Special precautions for disposal and other handling
Skyrizi is intended for use under the guidance and supervision of a healthcare professional.
Prior to use, a visual inspection of the cartridge is recommended. The solution is free from foreign particles and practically free from product-related particles. Skyrizi should not be used if the solution is cloudy or discoloured, or contains large particles.
The solution should be colourless to yellow and clear to slightly opalescent.
Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by any lesions.
Patients may self-inject Skyrizi using the cartridge with on-body injector after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of Skyrizi.
Before injecting, patients should remove the carton from the refrigerator and allow to reach room temperature (up to 25°C), out of direct sunlight, for 45 to 90 minutes without removing the cartridge from the carton.
Comprehensive instructions for use are provided in the package leaflet.
Each on-body injector with cartridge is for single use only.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
Each cartridge contains 360 mg of risankizumab in 2.4 mL solution (150 mg/mL).
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Solution for injection (injection)
The solution is colourless to yellow and clear to slightly opalescent.
## Clinical Particulars
4.1 Therapeutic indications
Crohn's disease
Risankizumab is indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable.
Ulcerative colitis
Skyrizi is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.4.2 Posology and method of administration
Skyrizi is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Skyrizi is indicated.
Posology
\*Crohn's disease\*
The recommended dose is 600 mg administered by intravenous infusion at Week 0, Week 4, and Week 8, followed by 360 mg administered by subcutaneous injection at Week 12, and every 8 weeks thereafter. Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the intravenous regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
\*Ulcerative colitis\*
The recommended induction dose is 1 200 mg administered by intravenous (IV) infusion at Week 0, Week 4, and Week 8. Starting at Week 12 and every 8 weeks thereafter, the recommended maintenance dose is based on individual patient presentation:
• A dose of 180 mg administered by subcutaneous injection is recommended for patients with adequate improvement in disease activity after induction
• A dose of 360 mg administered by subcutaneous injection is recommended for patients with inadequate improvement in disease activity after induction
Consideration should be given to discontinuing treatment in patients who have shown no evidence of therapeutic benefit by Week 24.
For the posology of the initial intravenous dosing regimen, see section 4.2 of the Skyrizi 600 mg concentrate for solution for infusion Summary of Product Characteristics.
Missed dose
If a dose is missed, the dose should be administered as soon as possible. Thereafter, dosing should be resumed at the regular scheduled time.
Special populations
\*Elderly\*
No dose adjustment is required (see section 5.2).
There is limited information in subjects aged ≥65 years.
\*Renal or hepatic impairment\*
No specific studies were conducted to assess the effect of hepatic or renal impairment on the pharmacokinetics of Skyrizi. These conditions are generally not expected to have any significant impact on the pharmacokinetics of monoclonal antibodies and no dose adjustments are considered necessary (see section 5.2).
\*Paediatric population\*
The safety and efficacy of Skyrizi for the treatment of Crohn's disease in children and adolescents younger than 16 years of age have not yet been established. The safety and efficacy of Skyrizi in children aged 0-17 years for the treatment of ulcerative colitis have not yet been established. Currently available data are described in section 5.1 and 5.2 but no recommendation on posology can be made.
\*Overweight patients\*
No dose adjustment is required (see section 5.2).
Method of administration
Skyrizi is administered by subcutaneous injection.
The injection should be administered in the thigh or abdomen. Patients should not inject into areas where the skin is tender, bruised, erythematous, indurated or damaged.
Patients may self-inject Skyrizi after training in subcutaneous injection technique with the on-body injector. Patients should be instructed to read the 'Instructions for use' provided in the package leaflet before administration.4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Clinically important active infections (e.g. active tuberculosis, see section 4.4).4.4 Special warnings and precautions for use
Traceability
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Infections
Risankizumab may increase the risk of infection.
In patients with a chronic infection, a history of recurrent infection, or known risk factors for infection, risankizumab should be used with caution. Treatment with risankizumab should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Patients treated with risankizumab should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops such an infection or is not responding to standard therapy for the infection, the patient should be closely monitored and risankizumab should not be administered until the infection resolves.
Tuberculosis
Prior to initiating treatment with risankizumab, patients should be evaluated for tuberculosis (TB) infection. Patients receiving risankizumab should be monitored for signs and symptoms of active TB. Anti-TB therapy should be considered prior to initiating risankizumab in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.
Immunisations
Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines. If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab. Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment (see section 5.2).
Hypersensitivity
Serious hypersensitivity reactions, including anaphylaxis, have been reported with use of risankizumab (see section 4.8). If a serious hypersensitivity reaction occurs, administration of risankizumab should be discontinued immediately and appropriate therapy initiated.
Excipients with known effect
This medicinal product contains less than 1 mmol sodium (23 mg) per cartridge, that is to say essentially 'sodium‑free'.4.5 Interaction with other medicinal products and other forms of interaction
Risankizumab is not expected to undergo metabolism by hepatic enzymes or renal elimination. Interactions between risankizumab and inhibitors, inducers, or substrates of medicinal product metabolising enzymes are not expected and no dose adjustment is needed (see section 5.2).
Concomitant immunosuppressive therapy
The safety and efficacy of risankizumab in combination with immunosuppressants, including biologics, have not been evaluated.4.6 Fertility, pregnancy and lactation
Women of childbearing potential
Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment.
Pregnancy
There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of risankizumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. As a precautionary measure, it is preferable to avoid the use of risankizumab during pregnancy.
Breast-feeding
It is unknown whether risankizumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which decreases to low concentrations soon afterwards; consequently, a risk to the breast-fed infant cannot be excluded during this short period. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.
Fertility
The effect of risankizumab on human fertility has not been evaluated. Animal studies do not indicate direct or indirect harmful effects with respect to fertility.4.7 Effects on ability to drive and use machines
Risankizumab has no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
Summary of the safety profile
The most frequently reported adverse reactions were upper respiratory infections (15.6% in Crohn's disease and 26.2% in ulcerative colitis).
Tabulated list of adverse reactions
Adverse reactions for risankizumab from clinical studies (Table 1) are listed by MedDRA system organ class and are based on the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥ 1/10 000 to < 1/1 000); and very rare (< 1/10 000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
\*\*Table 1: List of adverse reactions\*\*
| | | |
| --- | --- | --- |
| \*\*System Organ Class\*\* | \*\*Frequency\*\* | \*\*Adverse reactions\*\* |
| Infections and infestations | Very common | Upper respiratory infectionsa |
| Common | Tinea infectionsb |
| Uncommon | Folliculitis |
| Nervous system disorders | Common | Headachec |
| Skin and subcutaneous tissue disorders | Common | Pruritus Rash Eczema |
| Uncommon | Urticaria |
| General disorders and administration site conditions | Common | Fatigued Injection site reactionse |
| Immune system disorders | Rare | Anaphylactic reactions |
| a Includes: respiratory tract infection (viral, bacterial or unspecified), sinusitis (including acute), rhinitis, nasopharyngitis, pharyngitis (including viral), tonsillitis, laryngitis, peritonsillar abscess b Includes: tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, onychomycosis, tinea infection c Includes: headache, tension headache, sinus headache d Includes: fatigue, asthenia, malaise e Includes: injection site bruising, erythema, haematoma, haemorrhage, irritation, pain, pruritus, reaction, swelling, induration, hypersensitivity, nodule, rash, urticaria, vesicles, warmth; infusion site erythema, extravasation, reaction, swelling | | |
Description of selected adverse reactions
\*Psoriasis\*
\*Infections\*
Over the entire psoriasis programme including long-term exposure to risankizumab, the rate of infections was 75.5 events per 100 subject-years. The majority of cases were non-serious and mild to moderate in severity and did not lead to discontinuation of risankizumab. The rate of serious infections was 1.7 events per 100 subject-years (see section 4.4).
\*Crohn's disease\*
The adverse drug reaction profile observed in patients with Crohn's disease treated with risankizumab was consistent with the adverse drug reaction profile observed in patients across indications. No new adverse reactions were identified in risankizumab Crohn's disease studies.
\*Infections\*
The majority of infections were non‑serious and mild to moderate in severity and did not lead to discontinuation of risankizumab.
The rate of infections in the pooled data from the 12-week induction studies was 83.3 events per 100 subject‑years in subjects treated with risankizumab 600 mg IV compared to 117.7 events per 100 subject‑years in placebo. The rate of serious infections was 3.4 events per 100 subject-years in subjects treated with risankizumab 600 mg IV compared to 16.7 events per 100 subject-years in placebo (see section 4.4).
The rate of infections in the 52‑week maintenance study was 57.7 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 76.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 6.0 events per 100 subject-years in subjects treated with risankizumab 360 mg SC after risankizumab induction compared to 5.0 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
\*Ulcerative colitis\*
Overall, the safety profile observed in patients with ulcerative colitis treated with risankizumab was consistent with the safety profile observed in patients across indications.
\*Infections\*
The rate of infections in the pooled data from the 12-week induction study was 78.3 events per 100 subject‑years in subjects treated with risankizumab 1 200 mg intravenously compared to 74.2 events per 100 subject‑years in placebo. The rate of serious infections was 3.0 events per 100 subject-years in subjects treated with risankizumab 1 200 mg intravenously compared to 5.4 events per 100 subject‑years in placebo (see section 4.4).
The rate of infections in the 52-week maintenance study was 67.4 events per 100 subject‑years in subjects treated with risankizumab 180 mg subcutaneously and 56.5 events per 100 subject‑years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 64.6 events per 100 subject‑years in subjects who received placebo after risankizumab induction. The rate of serious infections was 1.1 events per 100 subject-years in subjects treated with risankizumab 180 mg subcutaneously and 0.6 events per 100 subject-years in subjects treated with risankizumab 360 mg subcutaneously after risankizumab induction compared to 2.3 events per 100 subject‑years in subjects who received placebo after risankizumab induction (see section 4.4).
\*Immunogenicity\*
As with all therapeutic proteins, there is the potential for immunogenicity with risankizumab. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
For subjects with Crohn's disease treated with risankizumab at the recommended IV induction and SC maintenance doses for up to 64 weeks in CD clinical trials, treatment-emergent anti-drug antibodies and neutralizing antibodies were detected in 3.4% (2/58) and 0% (0/58) of evaluated subjects, respectively.
For subjects with ulcerative colitis treated with risankizumab at the recommended intravenous induction and subcutaneous maintenance doses (180 mg or 360 mg) for up to 64 weeks in ulcerative colitis clinical trials, treatment-emergent anti-drug antibodies and neutralising antibodies were detected in 8.9% (8/90) and 6.7% (6/90) for the 180 mg SC dose, or 4.4% (4/91) and 2.2% (2/91) for the 360 mg SC dose, of evaluated subjects, respectively.
Antibodies to risankizumab including neutralizing antibodies were not associated with changes in clinical response or safety.
Elderly
There is limited safety information in subjects aged ≥65 years.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme:
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store4.9 Overdose
In the event of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment be instituted immediately.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC18
Mechanism of action
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds with high affinity to the p19 subunit of human interleukin 23 (IL-23) cytokine without binding to IL-12 and inhibits its interaction with the IL-23 receptor complex. IL-23 is a cytokine that is involved in inflammatory and immune responses. By blocking IL-23 from binding to its receptor, risankizumab inhibits IL-23-dependent cell signalling and release of proinflammatory cytokines.
Pharmacodynamic effects
In a study of subjects with psoriasis, expression of genes associated with the IL-23/IL-17 axis was decreased in the skin after single doses of risankizumab. Reductions in epidermal thickness, infiltration of inflammatory cells, and expression of psoriatic disease markers were also observed in psoriatic lesions.
In a Phase 2 study of subjects with Crohn's disease, expression of genes associated with the IL-23/Th17 axis were decreased in gut tissue after multiple doses of risankizumab. Reductions in faecal calprotectin (FCP), serum C reactive protein (CRP) and IL-22 were also observed after multiple doses in Phase 3 induction studies in Crohn's patients. Decreases in FCP, CRP and serum IL-22 were maintained out to Week 52 of the maintenance study.
In a Phase 2b/3 study of subjects with ulcerative colitis, statistically significant and clinically meaningful reduction from baseline was observed in the inflammatory biomarkers, FCP and CRP, and in the IL-23 pathway-associated biomarker, serum IL-22, at week 12 of the induction study. Decreases in FCP, CRP and serum IL-22 were maintained out to Week 52 of the maintenance study.
Clinical efficacy and safety
Skyrizi has been shown to improve signs and symptoms and health related quality of life, as well as decrease mucosal inflammation as measured by endoscopy.
\*Crohn's disease\*
The efficacy and safety of risankizumab were assessed in 1 419 subjects with moderately to severely active Crohn's disease in three multicentre, randomised, double-blind, placebo‑controlled clinical studies. Enrolled subjects were 16 years of age or older with a Crohn's Disease Activity Index (CDAI) of 220 to 450, an average daily stool frequency (SF) ≥4 and/or average daily abdominal pain score (APS) ≥2, and a Simple Endoscopic Score for CD (SES-CD) of ≥6, or ≥4 for isolated ileal disease, excluding the narrowing component and confirmed by a central reviewer.
There were two 12‑week intravenous induction studies (ADVANCE and MOTIVATE), which included a 12‑week extension period for subjects who did not achieve SF/APS clinical response at Week 12 (≥ 30% decrease in SF and/or ≥ 30% decrease in APS and both not worse than baseline) at Week 12. ADVANCE and MOTIVATE were followed by a 52‑week randomized withdrawal study of subcutaneous maintenance treatment (FORTIFY) that enrolled subjects with SF/APS clinical response to IV induction treatment, representing at least 64 weeks of therapy.
\*ADVANCE and MOTIVATE\*
In studies ADVANCE and MOTIVATE, subjects were randomized to receive risankizumab at either 600 mg (recommended dose), 1 200 mg, or placebo, at Week 0, Week 4, and Week 8.
In ADVANCE, 58% (491/850) subjects had failed or were intolerant to treatment with one or more biologic therapies (prior biologic failure), and 42% (359/850) had failed or were intolerant to therapy with conventional therapies but not biologic therapies (without prior biologic failure). In ADVANCE, among the subjects without prior biologic failure, (87%) 314/359 were naïve to biologic therapy and the remaining 13% had received a biologic but never failed or demonstrated intolerance. All patients in MOTIVATE had prior biologic failure.
The co-primary endpoints were clinical remission based on SF and APS (average daily SF ≤2.8 and not worse than baseline and average daily AP score ≤1 and not worse than baseline) at Week 12, and endoscopic response (greater than 50% decrease in SES‑CD from baseline, or a decrease of at least 2 points for subjects with a baseline score of 4 and isolated ileal disease) at Week 12. In both studies, a greater proportion of subjects treated with Skyrizi achieved clinical remission at Week 12 and endoscopic response at Week 12 compared to placebo (Table 2). Enhanced SF/APS clinical response and clinical remission were significant as early as Week 4 in subjects treated with Skyrizi and continued to improve through Week 12.
Additional secondary endpoints measured at Week 12 included the proportion of subjects with enhanced SF/APS clinical response (with ≥60% decrease in average daily SF and/or ≥35% decrease in average daily AP score and both not worse than Baseline, and/or clinical remission), endoscopic remission (SES-CD ≤4 and at least a 2 point reduction versus Baseline and no subscore greater than 1 in any individual variable), mucosal healing (SES-CD ulcerated surface subscore of 0 in subjects with a subscore of >1 at Baseline), a decrease of least 100 points in baseline CDAI, and a CDAI <150 at Week 12.
\*\*Table 2. Efficacy results in ADVANCE and MOTIVATE\*\*
| | | | | | | |
| --- | --- | --- | --- | --- | --- | --- |
| | \*\*ADVANCE\*\* | | | \*\*MOTIVATE\*\* | | |
| \*\*Placebo IV\*\* \*\*(N=175)\*\* \*\*%\*\* | \*\*Skyrizi\*\* \*\*600 mg IV\*\* \*\*(N=336)\*\* \*\*%\*\* | \*\*Treatment differencee (95% CI)\*\* | \*\*Placebo IV\*\* \*\*(N=187)\*\* \*\*%\*\* | \*\*Skyrizi\*\* \*\*600 mg IV\*\* \*\*(N=191)\*\* \*\*%\*\* | \*\*Treatment differencee\*\* \*\*(95% CI)\*\* |
| \*\*Clinical remission at Week 12a\*\* | 22% | 43% | 22% [14%, 30%]b | 19% | 35% | 15% [6%, 24%]c |
| \*\*Endoscopic response at Week 12a\*\* | 12% | 40% | 28% [21%, 35%]b | 11% | 29% | 18% [10%, 25%]b |
| \*\*Enhanced SF/APS clinical response at Week 4\*\* | 31% | 46% | 15% [6%, 23%]c | 32% | 45% | 14% [4%, 23%]d |
| \*\*Enhanced SF/APS clinical response at Week 12\*\* | 42% | 63% | 21% [12%, 30%]b | 39% | 62% | 23% [13%, 33%]b |
| \*\*Mucosal healing at Week 12\*\* | 8% | 21% | 14% [8%, 19%]b | 4% | 14% | 9% [4%, 15%]c |
| \*\*Endoscopic remission at Week 12\*\* | 9% | 24% | 15% [9%, 21%]b | 4% | 19% | 15% [9%, 21%]b |
| a Co-primary endpoints. b Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p<0.001). c Statistically significant under multiplicity-control for Skyrizi vs placebo (p≤0.01). d Nominal p ≤ 0.01 SKYRIZI vs placebo comparison. e Adjusted treatment difference. | | | | | | |
At Week 4, a higher proportion of subjects treated with Skyrizi achieved a CDAI <150 compared to placebo (ADVANCE, Skyrizi=18%, placebo=10%, p≤0.05; MOTIVATE, Skyrizi=21%, placebo=11%, p≤0.01).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved a CDAI<150 compared to placebo (ADVANCE, Skyrizi=45%, placebo=25%, p<0.001; MOTIVATE, Skyrizi=42%, placebo=20%, p<0.001).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved a decrease of at least 100 points in baseline CDAI compared to placebo (ADVANCE, Skyrizi=60%, placebo=37%, p<0.001; MOTIVATE, Skyrizi=60%, placebo=30%, p<0.001).
At Week 12, a higher proportion of subjects treated with Skyrizi achieved both enhanced SF/APS clinical response and endoscopic response at Week 12 compared to placebo (ADVANCE, Skyrizi=31%, placebo=8%, p<0.001; MOTIVATE, Skyrizi=21%, placebo=7%, p<0.001).
The results for the co-primary endpoints for subjects with and without prior biologic failure are presented in Table 3.
\*\*Table 3. Efficacy results at Week 12 in subjects with prior biologic treatment failure and subjects without prior biologic failure in ADVANCE\*\*
| | | |
| --- | --- | --- |
| | \*\*ADVANCE\*\* | |
| \*\*Placebo IV\*\* | \*\*Skyrizi 600 mg\*\* |
| \*\*Clinical remission per SF/AP Score\*\* | | |
| Prior biologic failure | 23% (N=97) | 41% (N=195) |
| Without prior biologic failure | 21% (N=78) | 48% (N=141) |
| \*\*Endoscopic response\*\* | | |
| Prior biologic failure | 11% (N=97) | 33% (N=195) |
| Without prior biologic failure | 13% (N=78) | 50% (N=141) |
In ADVANCE, a higher proportion of subjects treated with Skyrizi with and without prior biologic failure achieved CDAI<150 compared to placebo (With prior biologic failure, Skyrizi=42%, placebo=26%; Without prior biologic failure, Skyrizi=49%, placebo=23%).
\*CD-related hospitalisations\*
Rates of CD-related hospitalisations through Week 12 were lower in subjects treated with Skyrizi compared to placebo (ADVANCE, Skyrizi=3%, placebo=12%, p<0.001; MOTIVATE, Skyrizi=3%, placebo=11%, p≤0.01).
\*FORTIFY\*
The maintenance study FORTIFY evaluated 462 subjects with SF/APS clinical response to 12 weeks of Skyrizi IV induction treatment in studies ADVANCE and MOTIVIATE. Subjects were randomized to continue to receive a maintenance regimen of Skyrizi 360 mg SC (recommended dose), or Skyrizi 180 mg SC every 8 weeks, or to withdraw from Skyrizi induction and receive placebo SC every 8 weeks for up to 52 weeks.
The co-primary endpoints were clinical remission at Week 52 and, endoscopic response at Week 52. Co-primary endpoints were also measured in subjects with and without prior biologic failure (see Table 4).
Secondary endpoints measured at Week 52 included enhanced SF/APS clinical response, maintenance of clinical remission (clinical remission at Week 52 in subjects with clinical remission at Week 0), mucosal healing, endoscopic remission, deep remission (clinical remission and endoscopic remission), and CDAI <150.
\*\*Table 4. Efficacy results in FORTIFY at Week 52 (64 weeks from initiation of induction dose)\*\*
| | | | |
| --- | --- | --- | --- |
| | \*\*FORTIFY\*\* | | |
| \*\*Skyrizi IV induction/ Placebo SCg\*\* \*\*(N=164) %\*\* | \*\*Skyrizi IV induction/ Skyrizi\*\* \*\*360 mg SC\*\* \*\*(N=141) %\*\* | \*\*Treatment difference (95% CI)\*\* |
| \*\*Clinical remissiona\*\* | 40% | 52% | 15% [5%, 25%]b,h |
| Prior biologic failure | 34% (N=123) | 48% (N=102) | 14% [1%,27%] |
| Without prior biologic failure | 56% (N=41) | 62% (N=39) | 5% [-16%,27%] |
| \*\*Endoscopic responsea\*\* | 22% | 47% | 28% [19%, 37%]c,h |
| Prior biologic failure | 20% (N=123) | 44% (N=102) | 23% [11%, 35%] |
| Without biologic failure | 27% (N=41) | 54% (N=39) | 27% [6%, 48%] |
| \*\*Enhanced SF/APS clinical response\*\* | 49% | 59% | 13% [2%, 23%]f,h |
| \*\*Maintenance of clinical remission\*\* | (N = 91) 51% | (N = 72) 69% | 21% [6%, 35%]e,h |
| \*\*Endoscopic remission\*\* | 13% | 39% | 28% [20%, 37%]d,h |
| \*\*Mucosal healing\*\* | (N = 162) 10% | (N = 141) 31% | 22% [14%, 30%]d,h |
| a Co-primary endpoints b Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p≤0.01). c Statistically significant under multiplicity-control for Skyrizi vs placebo comparison (p≤0.001). d Nominal p<0.001 Skyrizi vs placebo comparison. e Nominal p≤0.01 Skyrizi vs placebo comparison. f Nominal p≤0.05 Skyrizi vs placebo comparison. g The induction-only group consisted of subjects who achieved clinical response to Skyrizi induction therapy and were randomized to receive placebo in the maintenance study (FORTIFY). h Adjusted treatment difference. | | | |
Deep remission at Week 52 was observed at higher rates in subjects treated with Skyrizi IV/Skyrizi SC compared to subjects who received Skyrizi IV/placebo SC (28% vs. 10%, respectively, p<0.001).
At Week 52, a higher proportion of subjects treated with Skyrizi IV/Skyrizi SC achieved CDAI < 150 compared to Skyrizi IV/placebo SC (52% vs. 41%, respectively, p≤0.01). A higher proportion of subjects treated with Skyrizi IV/Skyrizi SC achieved a decrease of at least 100 points in baseline CDAI score compared to subjects treated with Skyrizi IV/placebo SC (62% vs. 48%, respectively, p≤ 0.01).
91 subjects who did not demonstrate SF/APS clinical response 12 weeks after Skyrizi induction in studies ADVANCE and MOTIVATE received subcutaneous 360 mg dose of Skyrizi at Week 12 and Week 20. Of these subjects, 64% (58/91) achieved SF/APS clinical response at Week 24; 33 of the subjects achieving SF/APS clinical response enrolled in FORTIFY and continued receiving Skyrizi 360 mg SC every 8 weeks for up to 52 weeks. Among these subjects, 55% (18/33) achieved clinical remission and 45% (15/33) achieved endoscopic response at Week 52.
During FORTIFY, 30 subjects had loss of response to Skyrizi 360 mg SC treatment and received rescue treatment with Skyrizi (1 200 mg IV single dose, followed by 360 mg SC every 8 weeks). Of these subjects, 57% (17/30) achieved SF/APS clinical response at Week 52. In addition, 20% (6/30) and 34% (10/29) of subjects achieved clinical remission and endoscopic response at Week 52, respectively.
\*Health-related and quality of life outcomes\*
Health-related quality of life was assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ), 36-Item Short Form Health Survey (SF-36), and the European Quality of Life 5 Dimensions (EQ-5D). Improvement in fatigue was evaluated by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale.
At Week 12 of ADVANCE and MOTIVATE, subjects treated with Skyrizi achieved clinically meaningful improvements from baseline in IBDQ total score, all IBDQ domain scores (bowel symptoms, systemic function, emotional function, and social function), SF-36 Physical and Mental Component Summary Score, EQ-5D VAS, and FACIT-Fatigue compared to placebo.
Subjects treated with Skyrizi experienced more improvements in work productivity compared to placebo, as assessed by the WPAI-CD questionnaire at Week 12. Specifically, greater reductions in impairment while working, overall work impairment, and activity impairment was demonstrated in ADVANCE; and greater reduction in activity impairment was demonstrated in MOTIVATE.
Compared to placebo, subjects treated with Skyrizi achieved clinically meaningful improvements from baseline in Crohn's-related symptoms and sleep impact as assessed by Crohn's Symptom Severity (CSS) questionnaire at Week 12. These improvements were maintained in subjects treated with Skyrizi IV/Skyrizi SC in FORTIFY through Week 52.
\*Ulcerative colitis\*
The efficacy and safety of risankizumab was assessed in subjects with moderately to severely active ulcerative colitis in two multicentre, randomised, double-blind, placebo-controlled clinical studies. Enrolled subjects were ≥ 18 and ≤ 80 years of age with adapted Mayo Score (aMS) of 5 to 9 (using the Mayo scoring system, excluding Physician's Global Assessment) with an endoscopic subscore (ES) of 2 or 3 on screening endoscopy, confirmed by central review.
The 12-week intravenous induction study (INSPIRE) included a 12-week extension period for subjects who did not achieve clinical response [defined as a decrease from baseline in the aMS ≥ 2 points and ≥ 30% from baseline, and a decrease in rectal bleeding subscore (RBS) ≥ 1 or an absolute RBS ≤ 1] at Week 12. INSPIRE was followed by a 52-week randomised withdrawal study of subcutaneous maintenance treatment (COMMAND) that enrolled subjects with clinical response to 12 weeks of risankizumab intravenous induction treatment, representing at least 64 weeks of therapy.
\*INSPIRE\*
In study INSPIRE, 975 subjects were randomised and received either risankizumab 1 200 mg or placebo, at Week 0, Week 4, and Week 8.
In INSPIRE, 52% (503/975) of subjects had failed (inadequate response or intolerance) one or more biologics therapies, JAK inhibitors, and/or S1P receptor modulators. Of these 503 subjects, 488 (97%) failed biologics and 90 (18%) failed JAK inhibitors.
Enrolled subjects were permitted to use a stable dose of oral corticosteroids (up to 20 mg/day prednisone or equivalent), immunomodulators, and aminosalicylates. At baseline in INSPIRE, 36% of subjects received corticosteroids, 17% of subjects received immunomodulators and 73% of subjects received aminosalicylates. Patient disease activity was moderate (aMS ≤7) in 58% of subjects and severe (aMS >7) in 42% of subjects
In INSPIRE, a significantly greater proportion of subjects treated with risankizumab achieved the primary endpoint of clinical remission per aMS [defined as stool frequency subscore (SFS) ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability] at Week 12 compared to placebo (Table 5). Results of the primary endpoint and key secondary endpoints are listed in Table 5.
\*\*Table 5. Efficacy results in INSPIRE at Week 12\*\*
| | | | |
| --- | --- | --- | --- |
| \*\*Endpoint\*\* | \*\*Placebo IV\*\* \*\*(N=325)\*\* \*\*%\*\* | \*\*Risankizumab\*\* \*\*1 200 mg IV\*\* \*\*(N=650)\*\* \*\*%\*\* | \*\*Treatment difference\*\* \*\*(95% CI)\*\* |
| \*\*Disease activity and UC symptoms\*\* | | | |
| \*\*Clinical remissionab\*\* | 6% | 20% | 14%f [10%, 18%] |
| With biologic and/or JAK inhibitor failure | 4% (N=170) | 11% (N=333) | 7% [3%, 12%] |
| Without biologic and/or JAK inhibitor failure | 8% (N=155) | 30% (N=317) | 21% [15%, 28%] |
| \*\*Clinical responsec\*\* | 36% | 64% | 29%f [22%, 35%] |
| With biologic and/or JAK inhibitor failure | 31% (N=170) | 55% (N=333) | 24% [15%, 33%] |
| Without biologic and/or JAK inhibitor failure | 41% (N=155) | 74% (N=317) | 33% [24%, 42%] |
| \*\*Endoscopic and histologic assessment\*\* | | | |
| \*\*Mucosal healingd\*\* | 12% | 37% | 24%f [19%, 29%] |
| With biologic and/or JAK inhibitor failure | 10% (N=170) | 26% (N=333) | 16% [9%, 22%] |
| Without biologic and/or JAK inhibitor failure | 14% (N=155) | 48% (N=317) | 33% [26%, 41%] |
| \*\*Histologic-endoscopic mucosal healinge\*\* | 8% | 24% | 17%f [12%, 21%] |
| With biologic and/or JAK inhibitor failure | 7% (N=170) | 16% (N=333) | 9% [3%, 14%] |
| Without biologic and/or JAK inhibitor failure | 8% (N=155) | 33% (N=317) | 25% [18%, 32%] |
| a Primary endpoint b Clinical remission per aMS: SFS ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability c Clinical response per aMS: decrease from Baseline ≥ 2 points and ≥ 30%, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1 d ES ≤ 1 without the evidence of friability e ES ≤ 1 without the evidence of friability and Geboes score ≤ 3.1 (indicating neutrophil infiltration in <5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue) f p < 0.00001, adjusted treatment difference (95% CI) | | | |
\*Clinical disease activity and symptoms\*
The partial adapted Mayo score (paMS) is composed of SFS and RBS. Clinical response per paMS is defined as a decrease of ≥1 point and ≥30% from Baseline and a decrease in RBS ≥1 or an absolute RBS ≤1. The results of clinical response per paMS over time in INSPIRE are shown in Figure 1. Onset of efficacy was rapid with a greater proportion of subjects treated with risankizumab achieving clinical response as early as Week 4 compared to placebo (52% vs 31%, respectively, p < 0.00001).
\*\*Figure 1. Proportion of subjects achieving clinical response per paMS over time in induction study INSPIRE\*\*
A significantly greater proportion of subjects treated with risankizumab compared to placebo had no abdominal pain (36% vs 26%, respectively, p < 0.01) and no bowel urgency (44% vs 28%, respectively, p < 0.00001) at Week 12.
\*Other UC symptoms\*
Number of faecal incontinence episodes per week was reduced in a significantly greater amount in subjects treated with risankizumab compared to placebo at Week 12 (change from baseline in risankizumab = -3.8, placebo = -2.2, p = 0.00003).
The proportion of subjects who had no nocturnal bowel movements was significantly greater in subjects treated with risankizumab compared to placebo at Week 12 (67% vs 43%, respectively, p < 0.00001).
The proportion of subjects who had no tenesmus was significantly greater in subjects treated with risankizumab compared to placebo at Week 12 (49% vs 30%, respectively, p < 0.00001).
Number of days with sleep interruption due to UC symptoms per week were reduced in a significantly greater amount in subjects treated with risankizumab compared to placebo at Week 12 (change from baseline in risankizumab = -2.5, placebo = -1.5, p < 0.00001).
\*UC-related hospitalisations\*
Rates of UC-related hospitalisations through Week 12 were significantly lower in subjects treated with risankizumab compared to placebo (1% vs 6%, respectively, p < 0.00001).
\*Extended treatment in week 12 non-responders\*
A total of 141 subjects who did not demonstrate clinical response at week 12 of risankizumab induction in INSPIRE received either subcutaneous 180 mg or 360 mg dose of risankizumab at Week 12 and Week 20. Of the 71 subjects who received risankizumab 180 mg SC and 70 subjects who received risankizumab 360 mg SC, 56% and 57% achieved clinical response at Week 24, respectively.
COMMAND
The maintenance study COMMAND evaluated 548 subjects with clinical response after 12 weeks of risankizumab IV induction treatment in study INSPIRE. Subjects were randomised to receive a maintenance regimen of risankizumab 180 mg SC or 360 mg SC every 8 weeks, or to withdraw from risankizumab induction and receive placebo SC every 8 weeks for up to 52 weeks.
In COMMAND, 75% (411/548) of subjects had failed (inadequate response or intolerance) one or more biologics therapies, JAK inhibitors, and/or S1P receptor modulators prior to induction baseline. Of these 411 subjects, 407 (99%) failed biologics and 78 (19%) failed JAK inhibitors.
In COMMAND, a significantly greater proportion of the above 548 subjects treated with risankizumab 180 mg SC or risankizumab 360 mg SC achieved the primary endpoint of clinical remission per aMS at Week 52 compared to placebo (see Table 6). Results of the primary endpoint and key secondary endpoints are listed in Table 6.
\*\*Table 6. Efficacy results in COMMAND at week 52 (64 weeks from initiation of induction dose)\*\*
| | | | | | |
| --- | --- | --- | --- | --- | --- |
| \*\*Endpoint\*\* | \*\*Risankizumab IV induction/ Placebo SC+\*\* \*\*(N=183) %\*\* | \*\*Risankizumab IV induction/ Risankizumab 180 mg SC\*\* \*\*(N=179) %\*\* | \*\*Risankizumab IV induction/ Risankizumab 360 mg SC\*\* \*\*(N=186) %\*\* | \*\*Treatment difference\*\* \*\*(97.5% CI)++\*\* | |
| \*\*Risankizumab IV induction/ Risankizumab 180 mg SC\*\* | \*\*Risankizumab IV induction/ Risankizumab 360 mg SC\*\* |
| \*\*Disease activity and UC symptoms\*\* | | | | | |
| \*\*Clinical remissionab\*\* | 25% | 40% | 38% | 16%h [6%, 27%] | 14%h [4%, 24%] |
| With biologic and/or JAK inhibitor failure | 23% (N=138) | 37% (N=134) | 29% (N=139) | 13% [1%, 26%] | 6% [-6%, 18%] |
| Without biologic and/or JAK inhibitor failure | 31% (N=45) | 51% (N=45) | 62% (N=47) | 20% [-3%, 43%] | 31% [8%, 53%] |
| \*\*Maintenance of clinical remissionc\*\* | 40% (N=53) | 70% (N=44) | 50% (N=40) | 29%h [7%, 51%] | 13%k [-11%, 36%] |
| With biologic and/or JAK inhibitor failure | 37% (N=35) | 65% (N=26) | 44% (N=25) | 28% [0%, 56%] | 7% [-22%, 36%] |
| Without biologic and/or JAK inhibitor failure | 44% (N=18) | 77% (N=18) | 60% (N=15) | 33% [-2%, 67%] | 16% [-23%, 54%] |
| \*\*Corticosteroid-free clinical remissiond\*\* | 25% | 40% | 37% | 16% h [6%, 26%] | 14% h [3%, 24%] |
| With biologic and/or JAK inhibitor failure | 23% (N=138) | 36% (N=134) | 29% (N=139) | 13% [0%, 25%] | 6% [-6%, 18%] |
| Without biologic and/or JAK inhibitor failure | 31% (N=45) | 51% (N=45) | 60% (N=47) | 20% [-3%, 43%] | 28% [6%, 51%] |
| \*\*Clinical responsee\*\* | 52% | 68% | 62% | 17%i [6%, 28%] | 11%j [0%, 23%] |
| With biologic and/or JAK inhibitor failure | 46% (N=138) | 63% (N=134) | 57% (N=139) | 18% [4%, 31%] | 11% [-2%, 25%] |
| Without biologic and/or JAK inhibitor failure | 71% (N=45) | 82% (N=45) | 79% (N=47) | 11% [-9%, 31%] | 8% [-13%, 28%] |
| \*\*Endoscopic and histologic assessment\*\* | | | | | |
| \*\*Mucosal healingf\*\* | 32% | 51% | 48% | 20% h [9%, 31%] | 17% h [7%, 28%] |
| With biologic and/or JAK inhibitor failure | 30% (N=138) | 48% (N=134) | 39% (N=139) | 17% [4%, 30%] | 8% [-4%, 21%] |
| Without biologic and/or JAK inhibitor failure | 36% (N=45) | 60% (N=45) | 76% (N=47) | 24% [1%, 47%] | 41% [19%, 62%] |
| \*\*Histologic-endoscopic mucosal healingg\*\* | 23% | 43% | 42% | 20%h [10%, 31%] | 20% h [10%, 30%] |
| With biologic and/or JAK inhibitor failure | 22% (N=138) | 39% (N=134) | 33% (N=139) | 17% [5%, 29%] | 11% [-1%, 23%] |
| Without biologic and/or JAK inhibitor failure | 29% (N=45) | 55% (N=45) | 69% (N=47) | 26% [3%, 49%] | 40% [19%, 62%] |
| + The induction-only group consisted of subjects who achieved clinical response to risankizumab induction therapy and were randomised to receive placebo in the maintenance study (COMMAND). ++ Adjusted difference for the overall treatment difference. a Primary endpoint b Clinical remission per aMS: SFS ≤ 1, and not greater than baseline, RBS = 0, and ES ≤ 1 without evidence of friability c Clinical remission per aMS at Week 52 among subjects who achieved clinical remission at the end of induction treatment d Clinical remission per aMS at Week 52 and corticosteroid-free for ≥90 days e Clinical response per aMS: decrease from Baseline ≥ 2 points and ≥ 30%, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1 f ES of ≤ 1 without the evidence of friability g ES ≤ 1 without the evidence of friability and Geboes score ≤ 3.1 (indicating neutrophil infiltration in <5% of crypts, no crypt destruction and no erosions, ulcerations or granulation tissue) h Statistically significant under multiplicity-control for risankizumab vs placebo comparison (p ≤ 0.01). i Nominal p ≤ 0.01 risankizumab vs placebo comparison j Nominal p ≤ 0.05 risankizumab vs placebo comparison k p = 0.2234 | | | | | |
\*Clinical disease activity and symptoms\*
A significantly greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC compared to risankizumab IV/placebo had no abdominal pain (47% vs 30%, respectively, p < 0.001) and no bowel urgency (54% vs 31%, respectively, p < 0.00001) at Week 52. A greater proportion of subjects treated with risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo had no bowel urgency (49% vs 31%, respectively, p < 0.001) at Week 52, and a numerically higher proportion of subjects had no abdominal pain compared to risankizumab IV/placebo (38% vs 30%, respectively, p = 0.0895) at Week 52.
\*Other UC symptoms\*
The proportion of subjects who had no nocturnal bowel movements was greater in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo at Week 52 (42% and 43% vs 30%, p < 0.01 and p < 0.001, respectively).
The proportion of subjects who had no tenesmus was greater in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo at Week 52 (37% and 37% vs 23%, respectively, p < 0.01).
\*UC-related hospitalisations\*
Occurrence of UC-related hospitalisations through Week 52 were numerically lower in subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo (0.6 per 100 subject-years and 1.2 per 100 subject-years vs 3.1 per 100 subject-years, p = 0.0949 and p = 0.2531, respectively).
\*Endoscopic and histologic assessment\*
Endoscopic remission (normalisation of the endoscopic appearance of the mucosa) was defined as ES of 0. At Week 12 of INSPIRE, a significantly greater proportion of subjects treated with risankizumab compared to placebo achieved endoscopic remission (11% vs 3%, respectively, p < 0.00001). At Week 52 of COMMAND, a significantly greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo achieved endoscopic remission (23% and 24% vs 15%, respectively, p < 0.05).
Deep mucosal healing was defined as ES of 0 and Geboes score < 2.0 (indicating no neutrophil in crypts or lamina propria and no increase in eosinophil, no crypt destruction, and no erosions, ulcerations or granulation tissue). At Week 12 of INSPIRE, a significantly greater proportion of subjects treated with risankizumab compared to placebo achieved deep mucosal healing (6% vs 1%, respectively, p < 0.00001). At Week 52 of COMMAND, a numerically higher proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo achieved deep mucosal healing (13% and 16% vs 10%, p = 0.2062 and p = 0.0618, respectively).
In COMMAND, maintenance of mucosal healing at Week 52 (ES ≤1 without friability) was seen in a greater proportion of subjects treated with risankizumab IV/risankizumab 180 mg SC and risankizumab IV/risankizumab 360 mg SC compared to risankizumab IV/placebo among subjects who achieved mucosal healing at the end of induction (74% and 54% vs 47%, p < 0.01 and p = 0.5629, respectively).
\*Rescue treatment\*
During COMMAND, subjects who had loss of response to risankizumab SC treatment received rescue treatment with risankizumab (a single IV induction dose, followed by 360 mg SC every 8 weeks). Among these subjects, in the risankizumab 180 mg SC and risankizumab 360 mg SC treatment group, 85% (17/20) and 74% (26/35) achieved clinical response at Week 52, respectively. In addition, 24% (6/25) and 35% (13/37) of subjects achieved clinical remission per aMS, and 38% (10/26) and 45% (17/38) of subjects achieved endoscopic improvement at Week 52 in the risankizumab 180 mg SC and risankizumab 360 mg SC treatment group, respectively.
\*Week 24 responders\*
A total of 100 subjects did not demonstrate clinical response after 12 weeks of induction treatment, received either subcutaneous 180 mg (N=56) or 360 mg (N=44) dose of risankizumab at Week 12 and Week 20, demonstrated clinical response at week 24, and continued receiving risankizumab 180 mg or 360 mg SC every 8 weeks for up to 52 weeks in COMMAND. Among these subjects, 46% and 45% achieved clinical response per aMS at Week 52, and 18% and 23% achieved clinical remission per aMS at Week 52, for risankizumab 180 mg and 360 mg SC respectively.
\*Health-related and quality of life outcomes\*
Subjects treated with risankizumab achieved clinically meaningful improvements from baseline in the Inflammatory Bowel Disease Questionnaire (IBDQ) (bowel symptoms, systemic function, emotional function, and social function) compared to placebo. Changes from baseline in IBDQ total score at Week 12 with risankizumab compared to placebo were 42.6 and 24.3, respectively. Changes from baseline in IBDQ total score at Week 52 were 52.6, 50.3 and 35.0 in subjects treated with risankizumab IV/risankizumab 180 mg SC, risankizumab IV/risankizumab 360 mg SC and risankizumab IV/placebo, respectively.
Subjects receiving risankizumab experienced significantly greater improvement from baseline in fatigue, as measured by FACIT-F score at week 12 compared to placebo. Changes from baseline in FACIT-F score at Week 12 with risankizumab compared to placebo were 7.9 and 3.3, respectively. Changes from baseline in FACIT-F score at Week 52 were 10.9, 10.3 and 7.0 in subjects treated with risankizumab IV/risankizumab 180 mg SC, risankizumab IV/risankizumab 360 mg SC and risankizumab IV/placebo, respectively.
Paediatric population
The Medicines and Healthcare products Regulatory Agency has deferred the obligation to submit the results of studies with Skyrizi in one or more subsets of the paediatric population in the treatment of Crohn's disease and ulcerative colitis(see section 4.2 for information on paediatric use).5.2 Pharmacokinetic properties
The pharmacokinetics of risankizumab was similar between plaque psoriasis and psoriatic arthritis, and between Crohn's disease and ulcerative colitis.
Absorption
Risankizumab exhibited linear pharmacokinetics with dose-proportional increase in exposure across dose ranges of 18 to 360 mg and 0.25 to 1 mg/kg administered subcutaneously, and 200 to 1 800 mg and 0.01 to 5 mg/kg administered intravenously.
Following subcutaneous dosing of risankizumab, peak plasma concentrations were achieved between 3‑14 days after dosing with an estimated absolute bioavailability of 74-89%. With dosing of 150 mg at Week 0, Week 4 and every 12 weeks thereafter, estimated steady-state peak and trough plasma concentrations are 12 and 2 µg/mL, respectively.
In subjects with Crohn's disease treated with 600 mg IV induction dose at Weeks 0, 4, and 8 followed by 360 mg SC maintenance dose at Week 12 and every 8 weeks thereafter, maximum median peak and trough concentrations are estimated to be 156 and 38.8 µg/mL respectively during the induction period (Weeks 8-12) and steady state median peak and trough concentrations are estimated to be 28.0 and 8.13 ug/mL respectively during the maintenance period (Weeks 40-48).
In subjects with ulcerative colitis treated with 1 200 mg IV induction dose at weeks 0, 4, and 8 followed by 180 mg or 360 mg SC maintenance dose at Week 12 and every 8 weeks thereafter, maximum median peak and trough concentrations are estimated to be 350 and 87.7 µg/mL respectively during the induction period (Weeks 8-12) and steady-state median peak and trough concentrations are estimated to be 19.6 and 4.64 µg/mL for the 180 mg SC dose and 39.2 and 9.29 µg/mL for the 360 mg SC dose, respectively, during the maintenance period (weeks 40-48).
Distribution
The mean (±standard deviation) steady-state volume of distribution (Vss) of risankizumab was 11.4 (±2.7) L in Phase 3 studies in subjects with psoriasis, indicating that the distribution of risankizumab is primarily confined to the vascular and interstitial spaces. In a typical 70 kg subject with Crohn's disease, Vss was 7.68 L.
Biotransformation
Therapeutic IgG monoclonal antibodies are typically degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgGs. Risankizumab is not expected to be metabolised by cytochrome P450 enzymes.
Elimination
The mean (±standard deviation) systemic clearance (CL) of risankizumab was 0.3 (±0.1) L/day in Phase 3 studies in subjects with psoriasis. The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in subjects with psoriasis. For a typical 70 kg subject with Crohn's disease, CL was 0.30 L/day and terminal elimination half-life was 21 days.
As an IgG1 monoclonal antibody, risankizumab is not expected to be filtered by glomerular filtration in the kidneys or to be excreted as an intact molecule in the urine.
Linearity/non-linearity
Risankizumab exhibited linear pharmacokinetics with approximately dose-proportional increases in systemic exposure (Cmax and AUC) in the evaluated dose ranges of 18 to 360 mg or 0.25 to 1 mg/kg subcutaneous administration and 200 to 1 800 mg and 0.01 to 5 mg/kg administered intravenously in healthy subjects or subjects with psoriasis, Crohn's disease or ulcerative colitis.
Interactions
Interaction studies were conducted in subjects with plaque psoriasis, Crohn's disease, or ulcerative colitis to assess the effect of repeated administration of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) sensitive probe substrates. The exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), metoprolol (CYP2D6 substrate) and midazolam (CYP3A substrate) following risankizumab treatment were comparable to their exposures prior to risankizumab treatment, indicating no clinically meaningful interactions through these enzymes.
Population pharmacokinetic analyses indicated that risankizumab exposure was not impacted by concomitant medicinal products used by some subjects with plaque psoriasis during the clinical studies. Similar lack of impact by concomitant medications was observed based on population pharmacokinetic analyses in Crohn's disease or ulcerative colitis.
Special populations
\*Paediatric population\*
The pharmacokinetics of risankizumab in paediatric subjects under 16 years of age has not been established. Risankizumab exposures in 16- to 17‑year-old subjects with Crohn's disease were similar to those in adults. Age was not found to have any significant impact on risankizumab exposures based on the population pharmacokinetic analyses.
\*Elderly\*
Of the 2 234 subjects with plaque psoriasis exposed to risankizumab, 243 were 65 years or older and 24 subjects were 75 years or older. Of the 1 574 subjects with Crohn's disease exposed to risankizumab, 72 were 65 years or older. Of the 1 512 subjects with ulcerative colitis exposed to risankizumab, 103 were 65 years or older and 8 subjects were 75 years or older. No overall differences in risankizumab exposure were observed between older and younger subjects who received risankizumab.
\*Patients with renal or hepatic impairment\*
No specific studies have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of risankizumab. Based on population pharmacokinetic analyses, serum creatinine levels, creatinine clearance, or hepatic function markers (ALT/AST/bilirubin) did not have a meaningful impact on risankizumab clearance in subjects with psoriasis, Crohn's disease, or ulcerative colitis.
As an IgG1 monoclonal antibody, risankizumab is mainly eliminated via intracellular catabolism and is not expected to undergo metabolism via hepatic cytochrome P450 enzymes or renal elimination.
\*Body weight\*
Risankizumab clearance and volume of distribution increase as body weight increases which may result in reduced efficacy in subjects with high body weight (>130 kg). However, this observation is based on a limited number of subjects with plaque psoriasis. Body weight had no clinically meaningful impact on risankizumab exposure or efficacy in psoriatic arthritis, Crohn's disease, or ulcerative colitis. No dose adjustment based on body weight is currently recommended.
\*Gender or race\*
The clearance of risankizumab was not significantly influenced by gender or race in adult subjects with plaque psoriasis, Crohn's disease or ulcerative colitis. No clinically meaningful differences in risankizumab exposure were observed in Chinese or Japanese subjects compared to Caucasian subjects in clinical pharmacokinetic studies in healthy volunteers.5.3 Preclinical safety data
Nonclinical data revealed no special hazard for humans based on repeat-dose toxicity studies including safety pharmacology evaluations and an enhanced pre- and post- natal developmental toxicity study in cynomolgus monkeys at doses of up to 50 mg/kg/week, producing exposures 10 times the clinical exposures during induction at a dose of 600 mg IV every 4 weeks and 39 times the clinical exposures for maintenance when given 360 mg SC every 8 weeks for Crohn's disease. For ulcerative colitis, exposures were 5 times the clinical exposures during induction at a dose of 1 200 mg intravenously every 4 weeks and 65 or 32 times the clinical exposures for maintenance when given 180 or 360 mg SC every 8 weeks.
Mutagenicity and carcinogenicity studies have not been conducted with risankizumab. In a 26-week chronic toxicology study in cynomolgus monkeys at doses of up to 50 mg/kg/week (7 times the clinical exposures during induction at a dose of 600 mg IV every 4 weeks and 28 times the clinical exposures for maintenance when given 360 mg SC every 8 weeks for Crohn's disease and 3 times the clinical exposures during induction at a dose of 1 200 mg intravenously every 4 weeks and 45 or 23 times the clinical exposures for maintenance when given 180 or 360 mg SC every 8 weeks for ulcerative colitis), there were no pre-neoplastic or neoplastic lesions observed and no adverse immunotoxicity or cardiovascular effects were noted.
## Pharmaceutical Particulars
6.1 List of excipients
Sodium acetate trihydrate
Acetic acid
Trehalose dihydrate
Polysorbate 20
Water for injections6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
24 months6.4 Special precautions for storage
Store in a refrigerator (2°C - 8°C). Do not freeze.
The cartridge may be stored out of the refrigerator (up to a maximum of 25°C) for up to 24 hours.
Keep the cartridge in the outer carton in order to protect from light.6.5 Nature and contents of container
A 360 mg solution in a single‑use cartridge made with cyclic olefin resin with coated chlorobutyl rubber septum and coated chlorobutyl rubber piston as product-contact materials, and a resin cap. The cartridge assembly is co-packed with an on-body injector (administration device). The fluid path within the on-body injector contains polyvinyl chloride tubing and a stainless steel 29‑gauge needle. The on-body injector contains silver oxide-zinc batteries and an adhesive skin patch made from polyester with an acrylic adhesive. The administration device is designed for use with the provided 360 mg cartridge.
Skyrizi 360 mg is available in packs containing 1 cartridge and 1 on-body injector.6.6 Special precautions for disposal and other handling
Skyrizi is intended for use under the guidance and supervision of a healthcare professional.
Prior to use, a visual inspection of the cartridge is recommended. The solution is free from foreign particles and practically free from product-related particles. Skyrizi should not be used if the solution is cloudy or discoloured, or contains large particles.
The solution should be colourless to yellow and clear to slightly opalescent.
Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected by any lesions.
Patients may self-inject Skyrizi using the cartridge with on-body injector after training in subcutaneous injection technique. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of Skyrizi.
Before injecting, patients should remove the carton from the refrigerator and allow to reach room temperature (up to 25°C), out of direct sunlight, for 45 to 90 minutes without removing the cartridge from the carton.
Comprehensive instructions for use are provided in the package leaflet.
Each on-body injector with cartridge is for single use only.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Company Detail Path
- /organization/abbvie-ltd-united-kingdom
